Dynamics of the main parameters of structure-functional condition of the left ventricle myocardium in usage of combination antihypertension therapy for postmenopausal women with different obesity patterns

Aim. To assess the dynamics of the main structural and functional parameters of the left ventricle myocardium condition (LV) in postmenopausal women with arterial hypertension (AH) and different types of obesity: abdominal (AO) and gluteofemoral (GFO), taking combination hypotensive therapy: angiotensin-converting enzyme inhibitor (ACEi) or direct renin inhibitor (DRI).

Material and methods. Totally, 168 women studied with AH in postmenopause: 97 with AO and 71 with GFO. Women with different obesity types were randomized to therapy groups as ACEi+diuretic and DRI+diuretic. Follow-up lasted for 24 weeks.

Results. Combination therapy that included DRI, led to target values of BP in 90,2% of patients with AO and 90,9% with GFO. Usage of DRI in AO and GFO was followed by significant decrease of wall thickness, left ventricle myocardium mass (MMLV) — by 22,6% and 17,9%, MMLV index — by 23,1% and 18,8%,  respectively, (р<0,05), and parameters of diastolic function of LV. On therapy by ACEi+diuretic target values of BP were recorded in 71,4% of AO patients, and in 84,4% with GFO. In 24 weeks of ACEi usage with diuretic in AO and GFO, there was significant change of diastolic LV function (p<0,05). Comparative analysis showed that DRI therapy was better comparing to ACEi in AO patients with AO in the sense of the LV structural-functional improvement.

Conclusion. Usage of ACEi or DRI in combination with diuretic in postmenopause led to significant cardioprotection not depending on obesity type. In addition, in AO the usage of DRI+diuretic was advantageous comparing to ACEi+diuretic in the sense of hypertrophy regression and LV diastolic function improvement.

obesity, arterial hypertension, postmenopause, direct renin inhibitor, angiotensine converting enzyme inhibitor

1. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159-219.

2. Shal’nova SA, Deev AD, Kapustina AV, et al. The body weight and its contribution to mortality from cardiovascular diseases and all reasons among the Russian population. Cardiovascular Therapy and Prevention 2014; 13(1): 44-8. Russian (Шальнова С.А., Деев А.Д., Капустина А.В. и др. Масса тела и ее вклад в смерт- ность от сердечно-сосудистых заболеваний и всех причин среди российского населения. Кардиоваскулярная терапия и профилактика 2014; 13(1): 44-8).

3. Oganov RG, Timofeeva TN, Koltunov IE, et al. Epidemiology of an arterial hypertension in Russia. Results of federal monitoring in 2003 — 2010. Cardiovascular Therapy and Prevention 2011; 1: 9-13. Russian (Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты феде- рального мониторинга 2003-2010гг. Кардиоваскулярная терапия и профилак- тика 2011; 1: 9-13).

4. Skibitsky VV, Medvedeva JuN, Shuhardina EL, et al. Risk factors and structure of cardiovascular pathology at women in a climax of various genesis. Problems of women health 2007; 2(3): 21-8. Russian (Скибицкий В.В., Медведева Ю.Н., Шухардина Е.Л. и др. Факторы риска и структура кардиоваскулярной патологии у женщин в климаксе различного генеза. Проблемы женского здоровья 2007; 2(3): 21-8).

5. Diagnostics and treatment of arterial hypertension: Russian recommendations. System hypertension 2010; 3: 5-26. Russian (Диагностика и лечение артериаль- ной гипертензии: Российские рекомендации. Системные гипертензии 2010; 3: 5-26).

6. Poirier P, Giles TD, Bray GA, et al. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113: 898-918.

7. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric. 2006; 9 (Suppl.1): 19-27.

8. Astashkin EI, Glezer MG. Obesity and arterial hypertension. Problems of women health. 2008; 4(3): 23-33. Russian (Асташкин Е.И., Глезер М.Г. Ожирение и арте- риальная гипертония. Проблемы женского здоровья 2008; 4(3): 23-33).

9. Jordan J, Boye SW, Breton SL, et al. Antihypertensive treatment in patients with class 3 obesity. Ther Adv Endocrinol Metab. 2012; 3(3): 93-8.

10. Zaporowska-Stachowiak I, Hoffmann K, Bryl W, et al. Aliskiren — an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. Arch Med Sci. 2014; 10(4): 830-6.

11. Schmieder RE, Philipp T, Guerediaga J, et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens. 2009; 27(7): 1493-501.

12. Skibitsky VV, Skibitskaya SV, Fendrikova AV. Efficiency of the combined antigipertenzivny therapy at various types of obesity at women with an arterial hypertension in a postmenopause. Problems of women health. 2013; 1(8): 30-8. Russian (Скибицкий В.В., Скибицкая С.В., Фендрикова А.В. Эффективность комбинированной антигипертензивной терапии при различных типах ожирения у женщин с артериальной гипертонией в постменопаузе. Проблемы женского здоровья. 2013; 1(8): 30-8).

13. Muhin NA, Fomin VV. Activity of a renin of plasma — risk factor and an independent target of antigipertenzivny therapy: role of an aliskiren. Consilium Medicum. 2009; 11(10): 3-6. Russian (Мухин Н.А., Фомин В.В. Активность ренина плазмы — фактор риска и самостоятельная мишень антигипертензивной терапии: роль алискирена. Consilium Medicum. 2009; 11(10): 3-6).

14. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension. 2005; 46(5): 1069-76.

15. Stucchi P, Cano V, Ruiz-Gayo M, Fernández-Alfonso MS. Aliskiren reduces bodyweight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol. 2009; 158(3): 771-8.